ArticleMovement disorders clinical practice2022
Clozapine Is Severely Underused in Parkinson's Disease Patients.
Article in Movement disorders clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- ACKR1/Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).British journal of clinical pharmacology · 2026Guideline
- Management of Parkinson's disease psychosis-a European perspective.The Lancet regional health. Europe · 2026Review
- Consensus Molecules Associated with Parkinson's Disease.Neurology international · 2026Review
- Assessment of clozapine taste in healthy volunteers: evidence for non-aversive sensory profile.Therapeutic advances in psychopharmacology · 2026Article
- Nationwide analysis of real-world access to and use of device-aided therapies in Parkinson's disease: insights from the French National Healthcare Data System (2015-2021).BMJ neurology open · 2026Article
- Discontinuation of the Clozapine Risk Evaluation and Mitigation Strategy and Implications in Movement Disorders.Movement disorders clinical practice · 2025Article
- The FDA Has Ended Required Blood Monitoring for Clozapine Use-Will This Impact the Management of Parkinson's Disease Psychosis?Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Neuropsychiatric disorders in Parkinson's disease.Therapeutic advances in neurological disorders · 2025Review
- Sedation and sleep safety of pimavanserin for Parkinsons's disease psychosis: Review and exploratory analysis of clinical study data.Clinical parkinsonism & related disorders · 2025Review
- Clozapine for Quetiapine-Refractory Psychosis in Parkinson's Disease: A Long-Term Single-Center Retrospective Study.Parkinson's disease · 2025Article
- On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.CNS drugs · 2024Article
- Rethinking Clozapine: Lights and Shadows of a Revolutionary Drug.Brain sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.